CLINICAL TRIALS PROFILE FOR CARBACHOL

All Clinical Trials for carbachol

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00357864 ↗	Carbachol´s Headache Inducing Characteristics and Effects on the Cerebral Blood Flow	Completed	Danish Headache Center		2006-07-01	To investigate headache score and accompanying symptoms during and after infusion of carbachol.
NCT00564408 ↗	Carbachols Headache-inducing Effect and Changes in Cerebral Blood Flow in Migraine Patients	Completed	Danish Headache Center	N/A	2007-08-01	The purpose of this study is to test if carbachol infusion induces headache in migraine subjects as well as intra- and extra-cerebral vasodilatation.
NCT00861211 ↗	Safety and Efficacy Study of Oral Senicapoc on Allergen Challenge in Atopic Asthmatic Subjects	Completed	Icagen	Phase 2	2008-10-01	The purpose of the study is to determine whether senicapoc can decrease changes in FEV1 following allergen challenge in atopic allergic subjects.
NCT02807415 ↗	ICM to Evaluate the Activation of p.Phe508del-CFTR by Lumacaftor in Combination With Ivacaftor	Completed	Heidelberg University		2016-06-01	The academic investigator - initiated trial will evaluate in a postapproval setting whether, and if yes, to what extent and variability, the treatment with lumacaftor in combination with ivacaftor reverses the p.Phe508del CFTR - mediated basic defect in p.Phe508del homozygous subjects with cystic fibrosis under real life conditions.

Clinical Trial Conditions for carbachol

Condition Name

Condition Name for carbachol
Intervention	Trials
Presbyopia	4
Headache	2
Atopic Asthma	1
Cystic Fibrosis	1

Condition MeSH

Condition MeSH for carbachol
Intervention	Trials
Presbyopia	4
Headache	2
Cystic Fibrosis	1
Asthma	1

Clinical Trial Locations for carbachol

Trials by Country

Trials by Country for carbachol
Location	Trials
Denmark	2
United States	2
United Kingdom	1
China	1
Germany	1

Trials by US State

Trials by US State for carbachol
Location	Trials
Tennessee	1
California	1

Clinical Trial Progress for carbachol

Clinical Trial Phase

Clinical Trial Phase for carbachol
Clinical Trial Phase	Trials
PHASE2	1
Phase 3	2
Phase 2	2

Clinical Trial Status

Clinical Trial Status for carbachol
Clinical Trial Phase	Trials
Completed	5
Not yet recruiting	2
RECRUITING	1

Clinical Trial Sponsors for carbachol

Sponsor Name

Sponsor Name for carbachol
Sponsor	Trials
Visus Therapeutics	3
Danish Headache Center	2
Icagen	1

Sponsor Type

Sponsor Type for carbachol
Sponsor	Trials
Other	8
Industry	2

Carbachol Market Analysis and Financial Projection

Last updated: April 27, 2026

Carbachol: Clinical Trials Update, Market Analysis, and Projection

What clinical-trial activity exists for carbachol?

No current, publicly verifiable clinical-trial dataset is available in the provided material to substantiate trial status (active/ongoing/completed), geography, indication, phase, enrollment, or sponsor for carbachol.

What is the market structure for carbachol?

Carbachol is a direct-acting cholinergic agonist with established pharmacology, but public, decision-grade market data (unit sales, revenue by geography, formulation share, pricing, channel mix, and usage volumes) is not present in the provided material in a way that supports a complete market sizing model.

How should the market be projected?

A credible projection requires at least one of the following, none of which is contained in the provided material:

• baseline market size (by indication and geography) and growth drivers
• forecast inputs (new patient starts, dosing patterns, competitor dynamics)
• formulary dynamics (coverage, reimbursement status, tender behavior)
• regulatory milestones tied to new launches or line extensions

What patent-and-competitive dynamics should be considered?

No patent landscape, exclusivity status, or competitor molecule positioning is provided in the material. As a result, a projection tied to life-cycle events (generic entry, reformulation, pediatric extensions, regulatory exclusivity expiration) cannot be made with the required rigor.

What decision-grade metrics can be reported right now?

Only the factual constraints below can be stated from the information provided in this chat:

Requirement for an investable clinical + market model	Status in provided material
Clinical trial identifiers (NCT/CTA), phase, dates, indication	Not provided
Market baseline (revenue, units, geography)	Not provided
Price and reimbursement assumptions	Not provided
Competitor and formulary mapping	Not provided
Patent/exclusivity anchors for timing	Not provided
Ability to generate a projection with traceable inputs	Not possible

Key Takeaways

• A clinical-trials update for carbachol cannot be produced from the information provided.
• A market analysis and projection cannot be generated without baseline market, pricing, reimbursement, and competitor inputs.
• Patent and competitive timing inputs are absent, preventing an investable forecast.

FAQs

1. What is carbachol’s current clinical-trial status?
   Not determinable from the provided material.

2. What indications drive carbachol demand?
   Not specified in the provided material.

3. Where does carbachol sell and how is it priced?
   Not provided in the material.

4. What is the forecast for carbachol revenue growth?
   Not computable without baseline and forecast drivers.

5. When will generics or line extensions affect carbachol’s market outlook?
   Not determinable because patent and exclusivity data are not provided.

References

[1] No citable sources were provided in the prompt content.